Compare Revvity Inc (RVTY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Sony Group Corp — how do they compare? Revvity Inc trades at $154.68 (market cap $16.98B), while Sony Group Corp trades at $24.2 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 8.1× Revvity Inc's market cap, and Sony Group Corp pays the higher dividend (0.66%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Sony Group Corp for 96 Days on average.
| RVTY | SONY | |
|---|---|---|
Market Cap | $16.98B | $136.87B |
Volume | 1,456,900 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $157.36 | $30.26 |
52-Week Low | $82.26 | $19.32 |
Typical Hold Time | 12 Days | 96 Days |
Enterprise Value | $19.30B | $134.77B |
Dividend Yield | 0.18% | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Sony trades at $24.05, up 2.25% with mixed technical signals and neutral analyst sentiment. The company reported strong Q2 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent news highlights Sony's content strength and legal actions against AI companies for copyright infringement.
Sony presents a mixed investment case with strong cash flow generation and content portfolio offset by near-term profitability concerns. The stock's valuation appears reasonable with P/E of 20.34, but investors should monitor the company's ability to improve margins amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
